Results 291 to 300 of about 138,032 (344)

Hemophagocytic Lymphohistiocytosis as First Manifestation of Dual B‐Cell Neoplasms: A Case Report of Co‐Existing Multiple Myeloma and B‐Cell Lymphoma

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Hemophagocytic lymphohistiocytosis (HLH) is an immune disorder causing excessive inflammation and tissue damage. Lymphoma, especially T‐cell lymphoma, is the most common cause of HLH, while Multiple Myeloma (MM) is rarely associated. We present a 61‐year‐old man with spiking fevers, fatigue, and unintentional weight loss. The HLH was driven by
Carla Romagnoli, Alexandra Lyubimova, Leily Santos‐Carrion, Ferial Alloush, Vathany Sriganeshan, Andrea Noboa, Jacqueline C. Barrientos   +6 more
wiley   +1 more source

Outcome and response to different management regimens in pediatric patients with immune thrombocytopenia (ITP). [PDF]

Ann Hematol
AbdelAziz RA, El-Sayed D, Ahmed FEZ, Komy MA.   +3 more
europepmc   +1 more source

Global gene expression profiling of virulent and attenuated strains of Ehrlichia ruminantium: Toward the comprehension of pathogenesis [PDF]

, 2014
Emboule, Loïc, Gordon, Jonathan, Lebrigand, Kevin, Lefrançois, Thierry, Marcelino, Isabel, Mari, Bernard, Martinez, Dominique, Meyer, Damien, Pinarello, Valérie, Pruneau, Ludovic, Sheikboudou, Christian, Vachiery, Nathalie, Viari, Alain   +12 more
core  

Venous Thromboembolism in Aggressive B‐Cell Lymphoma Patients Treated with CD19 CAR‐T Therapy: Single‐Institution Study

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Background Large B‐cell lymphomas (LBCLs) are a common subtype of non‐Hodgkin lymphomas. CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy has revolutionized LBCL treatment, with high remission rates but also significant toxicities, including cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS).
Neha Venkatesh, Kevin Milligan, Julia Parrish, Yun Qing, Ryan Sun, Paolo Strati, Jeremy Ramdial, Amy Ayers, Sairah Ahmed, Cristhiam Rojas Hernandez   +9 more
wiley   +1 more source

Plasma interleukin-12 levels as a potential biomarker of fatigue and quality of life in patients with primary immune thrombocytopenia. [PDF]

Blood Res
Wadhera S, Jain A, Sahni A, Swain RN, Singh C, Jandial A, Aggarwal R, Hans R, Prakash G, Khadwal A, Grover S, Das R, Malhotra P.   +12 more
europepmc   +1 more source

Rosuvastatin in Combination With Bortezomib Promotes Osteogenesis in Myeloma Bone Disease by Inhibiting the Secretion of CCL3

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Background Myeloma bone disease (MBD) is a devastating complication of multiple myeloma (MM) and a primary cause of disability in affected patients. Its pathogenesis is driven by an imbalance in bone remodeling, largely attributed to the overexpression of C‐C motif chemokine ligand 3 (CCL3). While both bortezomib and statins have been reported
Fujun Qu, Mingxu Hui, Fan Yang, Bo Huang, Nian Liu, Yuchan He, Xiaotao Wang   +6 more
wiley   +1 more source

Platelet Recovery and Coexisting Conditions in Pediatric Immune Thrombocytopenia: Insights from a Tertiary Care Study. [PDF]

Children (Basel)
Singer CE, Andreea Gabriela M, Carmen S, Enescu A, Gaman S, Varut RM, Dalia D, Veronica ME, Vintilescu ȘB, Ionovici N, Dorin PI, Cristian-Cosmin A, Popescu C.   +12 more
europepmc   +1 more source

Spleen and Bruton's tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Clin Hematol Int
Vatvani AD, Hariyanto TI, Ramirez AC, Shabarek N.   +3 more
europepmc   +1 more source

Successful Salvage Treatment With Fostamatinib for an Adolescent Patient With Refractory Chronic Immune Thrombocytopenia. [PDF]

Cureus
Nishizawa M, Sakamoto K, Saito S, Nakazawa Y.   +3 more
europepmc   +1 more source